A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Narcolepsy
In brief
Narcolepsy is a sleep disorder in which patients are not able to maintain wakefulness or require treatment to maintain wakefulness during the daytime. Narcolepsy is a lifelong neurologic disease for which no cure has been clinically available. JZP441 is currently being developed for the treatment of narcolepsy type 1 (NT1). This study will assess the safety of efficacy of JZP441 in adult patients with NT1.
Key facts
- Study ID
- NCT06961266
- Run by
- Jazz Pharmaceuticals
- People needed
- 6
- Starts
- 2025-05-13
- Expected to finish
- 2026-01-29
- Last updated by the study team
- 2026-04-06
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Trial Site — Atlanta, Georgia, United States
- Clinical Trial Site — Cincinnati, Ohio, United States
- Clinical Trial Site — Columbia, South Carolina, United States
- Clinical Trial Site — Austin, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.